That kind of analytical technology alreadly exists. Biomoda will simply have to adapt cypath to the technology. The p-value was incredibly good. If FDA makes that metric the basis of their decision, this will be a slam-dunk approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.